Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

231 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis.
Vukotic R, Conti F, Fagiuoli S, Morelli MC, Pasulo L, Colpani M, Foschi FG, Berardi S, Pianta P, Mangano M, Donato MF, Malinverno F, Monico S, Tamè M, Mazzella G, Belli LS, Viganò R, Carrai P, Burra P, Russo FP, Lenci I, Toniutto P, Merli M, Loiacono L, Iemmolo R, Degli Antoni AM, Romano A, Picciotto A, Rendina M, Andreone P; AISF-SOFOLT Study group. Vukotic R, et al. Among authors: mazzella g. J Viral Hepat. 2017 Oct;24(10):858-864. doi: 10.1111/jvh.12712. Epub 2017 May 5. J Viral Hepat. 2017. PMID: 28370880
Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.
Conti F, Brillanti S, Buonfiglioli F, Vukotic R, Morelli MC, Lalanne C, Massari M, Foschi FG, Bernabucci V, Serio I, Prati GM, Negri E, Badia L, Caraceni P, Muratori P, Vitale G, Porro A, Morotti M, Mazzella G, Andreone P. Conti F, et al. Among authors: mazzella g. J Viral Hepat. 2017 Jun;24(6):454-463. doi: 10.1111/jvh.12663. Epub 2017 Feb 2. J Viral Hepat. 2017. PMID: 27976461
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals.
Casadei Gardini A, Foschi FG, Conti F, Petracci E, Vukotic R, Marisi G, Buonfiglioli F, Vitale G, Ravaioli F, Gitto S, Verucchi G, Lenzi M, Bolondi L, Mazzella G, Brillanti S, Andreone P; member of the Bologna DAA group. Casadei Gardini A, et al. Among authors: mazzella g. Dig Liver Dis. 2019 May;51(5):681-688. doi: 10.1016/j.dld.2018.09.016. Epub 2018 Sep 22. Dig Liver Dis. 2019. PMID: 30327251 Free article.
High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?
Berardi S, Lodato F, Gramenzi A, D'Errico A, Lenzi M, Bontadini A, Morelli MC, Tamè MR, Piscaglia F, Biselli M, Sama C, Mazzella G, Pinna AD, Grazi G, Bernardi M, Andreone P. Berardi S, et al. Among authors: mazzella g. Gut. 2007 Feb;56(2):237-42. doi: 10.1136/gut.2006.092064. Epub 2006 Jun 23. Gut. 2007. PMID: 16798778 Free PMC article.
Spleen Stiffness Measurements Predict the Risk of Hepatic Decompensation After Direct-Acting Antivirals in HCV Cirrhotic Patients.
Dajti E, Ravaioli F, Colecchia A, Marasco G, Bacchi Reggiani ML, Colli A, Alemanni LV, Tamè M, Andreone P, Brillanti S, Azzaroli F, Mazzella G, Festi D. Dajti E, et al. Among authors: mazzella g. Ultraschall Med. 2022 Jun;43(3):280-288. doi: 10.1055/a-1205-0367. Epub 2020 Jul 16. Ultraschall Med. 2022. PMID: 32674184 English.
Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study.
Lodato F, Azzaroli F, Brillanti S, Colecchia A, Tamé MR, Montagnani M, Muratori R, Giovanelli S, Feletti V, Bacchi Reggiani ML, Roda E, Mazzella G. Lodato F, et al. Among authors: mazzella g. J Viral Hepat. 2005 Sep;12(5):536-42. doi: 10.1111/j.1365-2893.2005.00638.x. J Viral Hepat. 2005. PMID: 16108771 Clinical Trial.
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation.
Lodato F, Berardi S, Gramenzi A, Mazzella G, Lenzi M, Morelli MC, Tame MR, Piscaglia F, Andreone P; Bologna Liver Transplantation Group (BLTG); Ballardini G, Bernardi M, Bianchi FB, Biselli M, Bolondi L, Cescon M, Colecchia A, D'Errico A, Del Gaudio M, Ercolani G, Grazi GL, Grigioni W, Lorenzini S, Pinna AD, Ravaioli M, Roda E, Sama C, Vivarelli M. Lodato F, et al. Among authors: mazzella g. Aliment Pharmacol Ther. 2008 Aug 15;28(4):450-7. doi: 10.1111/j.1365-2036.2008.03761.x. Epub 2008 Jun 11. Aliment Pharmacol Ther. 2008. PMID: 18549463 Clinical Trial.
Long-term leukocyte natural α-interferon and ribavirin treatment in hepatitis C virus recurrence after liver transplantation.
Tamè M, Buonfiglioli F, Del Gaudio M, Lisotti A, Cecinato P, Colecchia A, Azzaroli F, D'Errico A, Arena R, Calvanese C, Quarneti C, Ballardini G, Pinna AD, Mazzella G. Tamè M, et al. Among authors: mazzella g. World J Gastroenterol. 2013 Aug 28;19(32):5278-85. doi: 10.3748/wjg.v19.i32.5278. World J Gastroenterol. 2013. PMID: 23983430 Free PMC article.
231 results